Shuichiro Takahashi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Shuichiro Takahashi has a total of 144 co-authors. Here are the top co-authors by number of shared publications:
- Takanori Teshima
Department of Hematology, Hokkaido University Faculty of Medicine, Sapporo, Japan
7 shared publications - Daigo Hashimoto
Department of Hematology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
6 shared publications - Geoffrey R. Hill
Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA
6 shared publications Hiroyuki Ohigashi
Department of Hematology, Hokkaido University Faculty of Medicine and Graduate School of Medicine, Sapporo, Japan
5 shared publications- Motoko Koyama
Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA
5 shared publications - Ping Zhang
QIMR Berghofer, Brisbane, Australia
5 shared publications
Latest Publications
- 13 November 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 11 (125)
IFN-γ–driven MHC class II on gut epithelium induces cytolytic T H 1 cell differentiation and stem cell loss in graft-versus-host disease
The molecular cues by which CD4 T cells are invoked to mediate lethal gut graft-versus-host disease (GVHD) at the epithelial interface after allogeneic hematopoietic stem cell transplantation are unclear. Here, we demonstrate that MHC class II (MHCII) but not MHC class I expression by intestinal epithelial cells (IECs) within the first 3 days of transplantation promotes lethal GVHD in mice. This was dependent on direct IFN-γ–dependent induction of MHCII on IECs, which expanded perforin/granzyme B–expressing cytolytic donor T H 1 cell while restraining T H 17 cell differentiation locally within the ileum. In contrast, intestinal stem cells (ISCs) were preferentially and progressively depleted by cytolytic T H 1 cells as a result of IFN-γ–induced MHCII expression. Together, IEC-intrinsic IFN-γ signaling is critical for the MHCII-dependent early local generation of cytolytic T H 1 cells that thereafter mediate MHCII-dependent ISC deletion. These data demonstrate a critical IFN-γ–MHCII feed-forward axis in the initiation of cytolytic T H 1 cell–dependent gut disease.
- 13 November 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 11 (125)
IFN-γ–driven MHC class II on gut epithelium induces cytolytic T H 1 cell differentiation and stem cell loss in graft-versus-host disease
The molecular cues by which CD4 T cells are invoked to mediate lethal gut graft-versus-host disease (GVHD) at the epithelial interface after allogeneic hematopoietic stem cell transplantation are unclear. Here, we demonstrate that MHC class II (MHCII) but not MHC class I expression by intestinal epithelial cells (IECs) within the first 3 days of transplantation promotes lethal GVHD in mice. This was dependent on direct IFN-γ–dependent induction of MHCII on IECs, which expanded perforin/granzyme B–expressing cytolytic donor T H 1 cell while restraining T H 17 cell differentiation locally within the ileum. In contrast, intestinal stem cells (ISCs) were preferentially and progressively depleted by cytolytic T H 1 cells as a result of IFN-γ–induced MHCII expression. Together, IEC-intrinsic IFN-γ signaling is critical for the MHCII-dependent early local generation of cytolytic T H 1 cells that thereafter mediate MHCII-dependent ISC deletion. These data demonstrate a critical IFN-γ–MHCII feed-forward axis in the initiation of cytolytic T H 1 cell–dependent gut disease.
- 22 August 2024
- Published by American Society of Hematology in Blood
- Vol. 144 (8) , 904-913
GVHD targets organoid-forming bile duct stem cells in a TGF-β–dependent manner
Graft-versus-host disease (GVHD) is a major life-threatening complication that occurs after allogeneic hematopoietic cell transplantation (HCT). Although adult tissue stem cells have been identified as targets of GVHD in the skin and gut, their role in hepatic GVHD is yet to be clarified. In the current study, we explored the fate of bile duct stem cells (BDSCs), capable of generating liver organoids in vitro, during hepatic GVHD after allogeneic HCT. We observed a significant expansion of biliary epithelial cells (BECs) on injury early after allogeneic HCT. Organoid-forming efficiency from the bile duct was also significantly increased early after allogeneic HCT. Subsequently, the organoid-forming efficiency from bile ducts was markedly decreased in association with the reduction of BECs and the elevation of plasma concentrations of bilirubin, suggesting that GVHD targets BDSCs and impairs the resilience of BECs. The growth of liver organoids in the presence of liver-infiltrating mononuclear cells from allogeneic recipients, but not from syngeneic recipients, was significantly reduced in a transforming growth factor-β (TGF-β)–dependent manner. Administration of SB-431542, an inhibitor of TGF-β signaling, from day 14 to day 28, protected organoid-forming BDSCs against GVHD and mitigated biliary dysfunction after allogeneic HCT, suggesting that BDSCs are a promising therapeutic target for hepatic GVHD.
- 22 August 2024
- Published by American Society of Hematology in Blood
- Vol. 144 (8) , 904-913
GVHD targets organoid-forming bile duct stem cells in a TGF-β–dependent manner
Graft-versus-host disease (GVHD) is a major life-threatening complication that occurs after allogeneic hematopoietic cell transplantation (HCT). Although adult tissue stem cells have been identified as targets of GVHD in the skin and gut, their role in hepatic GVHD is yet to be clarified. In the current study, we explored the fate of bile duct stem cells (BDSCs), capable of generating liver organoids in vitro, during hepatic GVHD after allogeneic HCT. We observed a significant expansion of biliary epithelial cells (BECs) on injury early after allogeneic HCT. Organoid-forming efficiency from the bile duct was also significantly increased early after allogeneic HCT. Subsequently, the organoid-forming efficiency from bile ducts was markedly decreased in association with the reduction of BECs and the elevation of plasma concentrations of bilirubin, suggesting that GVHD targets BDSCs and impairs the resilience of BECs. The growth of liver organoids in the presence of liver-infiltrating mononuclear cells from allogeneic recipients, but not from syngeneic recipients, was significantly reduced in a transforming growth factor-β (TGF-β)–dependent manner. Administration of SB-431542, an inhibitor of TGF-β signaling, from day 14 to day 28, protected organoid-forming BDSCs against GVHD and mitigated biliary dysfunction after allogeneic HCT, suggesting that BDSCs are a promising therapeutic target for hepatic GVHD.
- Open Access
- 30 April 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 134 (11) , 19
Calcineurin inhibition rescues alloantigen-specific central memory T cell subsets that promote chronic GVHD
Calcineurin inhibitors (CNIs) constitute the backbone of modern acute graft-versus-host disease (aGVHD) prophylaxis regimens but have limited efficacy in the prevention and treatment of chronic GVHD (cGVHD). We investigated the effect of CNIs on immune tolerance after stem cell transplantation with discovery-based single-cell gene expression and T cell receptor (TCR) assays of clonal immunity in tandem with traditional protein-based approaches and preclinical modeling. While cyclosporin and tacrolimus suppressed the clonal expansion of CD8 + T cells during GVHD, alloreactive CD4 + T cell clusters were preferentially expanded. Moreover, CNIs mediated reversible dose-dependent suppression of T cell activation and all stages of donor T cell exhaustion. Critically, CNIs promoted the expansion of both polyclonal and TCR-specific alloreactive central memory CD4 + T cells (T CM ) with high self-renewal capacity that mediated cGVHD following drug withdrawal. In contrast to posttransplant cyclophosphamide (PT-Cy), CSA was ineffective in eliminating IL-17A–secreting alloreactive T cell clones that play an important role in the pathogenesis of cGVHD. Collectively, we have shown that, although CNIs attenuate aGVHD, they paradoxically rescue alloantigen-specific T CM , especially within the CD4 + compartment in lymphoid and GVHD target tissues, thus predisposing patients to cGVHD. These data provide further evidence to caution against CNI-based immune suppression without concurrent approaches that eliminate alloreactive T cell clones.
- 30 April 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 134 (11) , 19
Open AccessCalcineurin inhibition rescues alloantigen-specific central memory T cell subsets that promote chronic GVHD
Calcineurin inhibitors (CNIs) constitute the backbone of modern acute graft-versus-host disease (aGVHD) prophylaxis regimens but have limited efficacy in the prevention and treatment of chronic GVHD (cGVHD). We investigated the effect of CNIs on immune tolerance after stem cell transplantation with discovery-based single-cell gene expression and T cell receptor (TCR) assays of clonal immunity in tandem with traditional protein-based approaches and preclinical modeling. While cyclosporin and tacrolimus suppressed the clonal expansion of CD8 + T cells during GVHD, alloreactive CD4 + T cell clusters were preferentially expanded. Moreover, CNIs mediated reversible dose-dependent suppression of T cell activation and all stages of donor T cell exhaustion. Critically, CNIs promoted the expansion of both polyclonal and TCR-specific alloreactive central memory CD4 + T cells (T CM ) with high self-renewal capacity that mediated cGVHD following drug withdrawal. In contrast to posttransplant cyclophosphamide (PT-Cy), CSA was ineffective in eliminating IL-17A–secreting alloreactive T cell clones that play an important role in the pathogenesis of cGVHD. Collectively, we have shown that, although CNIs attenuate aGVHD, they paradoxically rescue alloantigen-specific T CM , especially within the CD4 + compartment in lymphoid and GVHD target tissues, thus predisposing patients to cGVHD. These data provide further evidence to caution against CNI-based immune suppression without concurrent approaches that eliminate alloreactive T cell clones.
- 19 April 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 9 (94) , eadg1094
TIM-3 + CD8 T cells with a terminally exhausted phenotype retain functional capacity in hematological malignancies
Chronic antigen stimulation is thought to generate dysfunctional CD8 T cells. Here, we identify a CD8 T cell subset in the bone marrow tumor microenvironment that, despite an apparent terminally exhausted phenotype (T PHEX ), expressed granzymes, perforin, and IFN-γ. Concurrent gene expression and DNA accessibility revealed that genes encoding these functional proteins correlated with BATF expression and motif accessibility. IFN-γ + T PHEX effectively killed myeloma with comparable efficacy to transitory effectors, and disease progression correlated with numerical deficits in IFN-γ + T PHEX . We also observed IFN-γ + T PHEX within CD19-targeted chimeric antigen receptor T cells, which killed CD19 + leukemia cells. An IFN-γ + T PHEX gene signature was recapitulated in T EX cells from human cancers, including myeloma and lymphoma. Here, we characterize a T EX subset in hematological malignancies that paradoxically retains function and is distinct from dysfunctional T EX found in chronic viral infections. Thus, IFN-γ + T PHEX represent a potential target for immunotherapy of blood cancers.
- 19 April 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 9 (94) , eadg1094
TIM-3 + CD8 T cells with a terminally exhausted phenotype retain functional capacity in hematological malignancies
Chronic antigen stimulation is thought to generate dysfunctional CD8 T cells. Here, we identify a CD8 T cell subset in the bone marrow tumor microenvironment that, despite an apparent terminally exhausted phenotype (T PHEX ), expressed granzymes, perforin, and IFN-γ. Concurrent gene expression and DNA accessibility revealed that genes encoding these functional proteins correlated with BATF expression and motif accessibility. IFN-γ + T PHEX effectively killed myeloma with comparable efficacy to transitory effectors, and disease progression correlated with numerical deficits in IFN-γ + T PHEX . We also observed IFN-γ + T PHEX within CD19-targeted chimeric antigen receptor T cells, which killed CD19 + leukemia cells. An IFN-γ + T PHEX gene signature was recapitulated in T EX cells from human cancers, including myeloma and lymphoma. Here, we characterize a T EX subset in hematological malignancies that paradoxically retains function and is distinct from dysfunctional T EX found in chronic viral infections. Thus, IFN-γ + T PHEX represent a potential target for immunotherapy of blood cancers.
- Open Access
- 15 February 2023
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 133 (4)
TIGIT inhibition and lenalidomide synergistically promote antimyeloma immune responses after stem cell transplantation in mice
Autologous stem cell transplantation (ASCT) with subsequent lenalidomide maintenance is standard consolidation therapy for multiple myeloma, and a subset of patients achieve durable progression-free survival that is suggestive of long-term immune control. Nonetheless, most patients ultimately relapse, suggesting immune escape. TIGIT appears to be a potent inhibitor of myeloma-specific immunity and represents a promising new checkpoint target. Here we demonstrate high expression of TIGIT on activated CD8+ T cells in mobilized peripheral blood stem cell grafts from patients with myeloma. To guide clinical application of TIGIT inhibition, we evaluated identical anti-TIGIT antibodies that do or do not engage FcγR and demonstrated that anti-TIGIT activity is dependent on FcγR binding. We subsequently used CRBN mice to investigate the efficacy of anti-TIGIT in combination with lenalidomide maintenance after transplantation. Notably, the combination of anti-TIGIT with lenalidomide provided synergistic, CD8+ T cell–dependent, antimyeloma efficacy. Analysis of bone marrow (BM) CD8+ T cells demonstrated that combination therapy suppressed T cell exhaustion, enhanced effector function, and expanded central memory subsets. Importantly, these immune phenotypes were specific to the BM tumor microenvironment. Collectively, these data provide a logical rationale for combining TIGIT inhibition with immunomodulatory drugs to prevent myeloma progression after ASCT.
- 15 February 2023
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 133 (4)
Open AccessTIGIT inhibition and lenalidomide synergistically promote antimyeloma immune responses after stem cell transplantation in mice
Autologous stem cell transplantation (ASCT) with subsequent lenalidomide maintenance is standard consolidation therapy for multiple myeloma, and a subset of patients achieve durable progression-free survival that is suggestive of long-term immune control. Nonetheless, most patients ultimately relapse, suggesting immune escape. TIGIT appears to be a potent inhibitor of myeloma-specific immunity and represents a promising new checkpoint target. Here we demonstrate high expression of TIGIT on activated CD8+ T cells in mobilized peripheral blood stem cell grafts from patients with myeloma. To guide clinical application of TIGIT inhibition, we evaluated identical anti-TIGIT antibodies that do or do not engage FcγR and demonstrated that anti-TIGIT activity is dependent on FcγR binding. We subsequently used CRBN mice to investigate the efficacy of anti-TIGIT in combination with lenalidomide maintenance after transplantation. Notably, the combination of anti-TIGIT with lenalidomide provided synergistic, CD8+ T cell–dependent, antimyeloma efficacy. Analysis of bone marrow (BM) CD8+ T cells demonstrated that combination therapy suppressed T cell exhaustion, enhanced effector function, and expanded central memory subsets. Importantly, these immune phenotypes were specific to the BM tumor microenvironment. Collectively, these data provide a logical rationale for combining TIGIT inhibition with immunomodulatory drugs to prevent myeloma progression after ASCT.
- Open Access
- 21 November 2022
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 119 (48)
Reactive granulopoiesis depends on T-cell production of IL-17A and neutropenia-associated alteration of gut microbiota
Granulopoiesis in the bone marrow adjusts cellular output as demand for neutrophils changes. Reactive granulopoiesis is induced by profound neutropenia, but its mechanism remains to be clarified. We herein explored its mechanisms using mouse models of syngeneic hematopoietic stem cell transplantation (SCT) and 5-fluorouracil-induced neutropenia. After SCT, T cell production of IL-17A was up-regulated. Neutrophil recovery was significantly delayed in IL-17A-deficient or T cell-deficient RAG1 −/− mice, and adoptive transfer of wild-type ( WT ) T cells facilitated neutrophil engraftment. Gut decontamination with oral antibiotics suppressed T cell production of IL-17A and impaired neutrophil recovery. Transplantation of fecal microbiota collected from neutropenic, not naive, mice promoted neutrophil recovery in these mice, suggesting that neutropenia-associated microbiota had a potential to stimulate reactive granulopoiesis. Our study uncovered a cross talk between gut microbiota and neutropenia after SCT and chemotherapy.
- 21 November 2022
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 119 (48)
Open AccessReactive granulopoiesis depends on T-cell production of IL-17A and neutropenia-associated alteration of gut microbiota
Granulopoiesis in the bone marrow adjusts cellular output as demand for neutrophils changes. Reactive granulopoiesis is induced by profound neutropenia, but its mechanism remains to be clarified. We herein explored its mechanisms using mouse models of syngeneic hematopoietic stem cell transplantation (SCT) and 5-fluorouracil-induced neutropenia. After SCT, T cell production of IL-17A was up-regulated. Neutrophil recovery was significantly delayed in IL-17A-deficient or T cell-deficient RAG1 −/− mice, and adoptive transfer of wild-type ( WT ) T cells facilitated neutrophil engraftment. Gut decontamination with oral antibiotics suppressed T cell production of IL-17A and impaired neutrophil recovery. Transplantation of fecal microbiota collected from neutropenic, not naive, mice promoted neutrophil recovery in these mice, suggesting that neutropenia-associated microbiota had a potential to stimulate reactive granulopoiesis. Our study uncovered a cross talk between gut microbiota and neutropenia after SCT and chemotherapy.
- Open Access
- 22 November 2021
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 6 (22)
Peritransplant glucocorticoids redistribute donor T cells to the bone marrow and prevent relapse after haploidentical SCT
Patients with acute leukemia who are unable to achieve complete remission prior to allogeneic hematopoietic stem cell transplantation (SCT) have dismal outcomes, with relapse rates well in excess of 60%. Haplo-identical SCT (haplo-SCT) may allow enhanced graft-versus-leukemia (GVL) effects by virtue of HLA class I/II donor-host disparities, but it typically requires intensive immunosuppression with posttransplant cyclophosphamide (PT-Cy) to prevent lethal graft-versus-host disease (GVHD). Here, we demonstrate in preclinical models that glucocorticoid administration from days –1 to +5 inhibits alloantigen presentation by professional recipient antigen presenting cells in the gastrointestinal tract and prevents donor T cell priming and subsequent expansion therein. In contrast, direct glucocorticoid signaling of donor T cells promotes chemokine and integrin signatures permissive of preferential circulation and migration into the BM, promoting donor T cell residency. This results in significant reductions in GVHD while promoting potent GVL effects; relapse in recipients receiving glucocorticoids, vehicle, or PT-Cy was 12%, 56%, and 100%, respectively. Intriguingly, patients with acute myeloid leukemia not in remission who received unmanipulated haplo-SCT and peritransplant glucocorticoids also had an unexpectedly low relapse rate at 1 year (32%; 95% CI, 18%–47%) with high overall survival at 3 years (58%; 95% CI, 38%–74%). These data highlight a potentially simple and effective approach to prevent relapse in patients with otherwise incurable leukemia that could be studied in prospective randomized trials.
- 22 November 2021
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 6 (22)
Open AccessPeritransplant glucocorticoids redistribute donor T cells to the bone marrow and prevent relapse after haploidentical SCT
Patients with acute leukemia who are unable to achieve complete remission prior to allogeneic hematopoietic stem cell transplantation (SCT) have dismal outcomes, with relapse rates well in excess of 60%. Haplo-identical SCT (haplo-SCT) may allow enhanced graft-versus-leukemia (GVL) effects by virtue of HLA class I/II donor-host disparities, but it typically requires intensive immunosuppression with posttransplant cyclophosphamide (PT-Cy) to prevent lethal graft-versus-host disease (GVHD). Here, we demonstrate in preclinical models that glucocorticoid administration from days –1 to +5 inhibits alloantigen presentation by professional recipient antigen presenting cells in the gastrointestinal tract and prevents donor T cell priming and subsequent expansion therein. In contrast, direct glucocorticoid signaling of donor T cells promotes chemokine and integrin signatures permissive of preferential circulation and migration into the BM, promoting donor T cell residency. This results in significant reductions in GVHD while promoting potent GVL effects; relapse in recipients receiving glucocorticoids, vehicle, or PT-Cy was 12%, 56%, and 100%, respectively. Intriguingly, patients with acute myeloid leukemia not in remission who received unmanipulated haplo-SCT and peritransplant glucocorticoids also had an unexpectedly low relapse rate at 1 year (32%; 95% CI, 18%–47%) with high overall survival at 3 years (58%; 95% CI, 38%–74%). These data highlight a potentially simple and effective approach to prevent relapse in patients with otherwise incurable leukemia that could be studied in prospective randomized trials.
- 1 July 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 12 (550)
Intestinal goblet cells protect against GVHD after allogeneic stem cell transplantation via Lypd8
Goblet cells play a protective role against GVHD after allogeneic stem cell transplantation in a Lypd8-dependent manner.
- 1 July 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 12 (550)
Intestinal goblet cells protect against GVHD after allogeneic stem cell transplantation via Lypd8
Goblet cells play a protective role against GVHD after allogeneic stem cell transplantation in a Lypd8-dependent manner.
- Open Access
- 25 February 2020
- Published by Japan Society of Transfusion Medicine and Cell Therapy in Japanese Journal of Transfusion and Cell Therapy
- Vol. 66 (1) , 31-35
ABO BLOOD GROUP TYPING REACTIVITY TO CISAB IN A NEWBORN BABY AND DEVELOPMENTAL CHANGE IN ABO ANTIGEN LEVEL
CisA2B3型はオモテ検査での抗A,抗Bの反応が弱く,血漿中に抗Bが認められる反応態度であるが1),新生児におけるcisA2B3型の反応態度に関する報告は少ない.今回,cisA2B3型が疑われる新生児の血液型反応態度と成長に伴う血液型抗原量の変化について検討した. 症例は日齢0日の新生児.ABO血液型検査はカラム凝集法にてオモテ検査のみ施行し,抗A:2+,抗B:0となった.母親が血清学的検査でcisA2B3型と疑われていたことから,児の血液型精査,母児のABO遺伝子タイピング,血液型抗原量を測定した.児の赤血球の抗B吸着解離試験よりB抗原が検出され,ABO遺伝子タイピングでは母児共にcisAB01/O01と判定された.血液型抗原量は母親と比較して児のA,B抗原量は低く,特にB抗原量が著しく低かった.1歳11カ月時に再検査したところ,児のB抗原量は出生時よりも増加し,血漿中から抗Bが検出された. 新生児のcisAB型では通常の血液型検査では検出できないB抗原量であるため,血液型判定に際しcisAB型を疑う場合はABO遺伝子タイピングや血液型抗原量の測定が有用であることが示唆された.
- 25 February 2020
- Published by Japan Society of Transfusion Medicine and Cell Therapy in Japanese Journal of Transfusion and Cell Therapy
- Vol. 66 (1) , 31-35
Open AccessABO BLOOD GROUP TYPING REACTIVITY TO CISAB IN A NEWBORN BABY AND DEVELOPMENTAL CHANGE IN ABO ANTIGEN LEVEL
CisA2B3型はオモテ検査での抗A,抗Bの反応が弱く,血漿中に抗Bが認められる反応態度であるが1),新生児におけるcisA2B3型の反応態度に関する報告は少ない.今回,cisA2B3型が疑われる新生児の血液型反応態度と成長に伴う血液型抗原量の変化について検討した. 症例は日齢0日の新生児.ABO血液型検査はカラム凝集法にてオモテ検査のみ施行し,抗A:2+,抗B:0となった.母親が血清学的検査でcisA2B3型と疑われていたことから,児の血液型精査,母児のABO遺伝子タイピング,血液型抗原量を測定した.児の赤血球の抗B吸着解離試験よりB抗原が検出され,ABO遺伝子タイピングでは母児共にcisAB01/O01と判定された.血液型抗原量は母親と比較して児のA,B抗原量は低く,特にB抗原量が著しく低かった.1歳11カ月時に再検査したところ,児のB抗原量は出生時よりも増加し,血漿中から抗Bが検出された. 新生児のcisAB型では通常の血液型検査では検出できないB抗原量であるため,血液型判定に際しcisAB型を疑う場合はABO遺伝子タイピングや血液型抗原量の測定が有用であることが示唆された.